cgp 54626 has been researched along with 3,4-dihydroxyphenylglycol in 1 studies
Studies (cgp 54626) | Trials (cgp 54626) | Recent Studies (post-2010) (cgp 54626) | Studies (3,4-dihydroxyphenylglycol) | Trials (3,4-dihydroxyphenylglycol) | Recent Studies (post-2010) (3,4-dihydroxyphenylglycol) |
---|---|---|---|---|---|
57 | 0 | 16 | 932 | 55 | 191 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bernier, BE; Clements, MA; Morikawa, H; Perra, S | 1 |
1 other study(ies) available for cgp 54626 and 3,4-dihydroxyphenylglycol
Article | Year |
---|---|
In vivo ethanol experience increases D(2) autoinhibition in the ventral tegmental area.
Topics: Action Potentials; Analysis of Variance; Animals; Baclofen; Central Nervous System Depressants; Chelating Agents; Dopamine; Dopamine Agents; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Egtazic Acid; Electric Stimulation; Enzyme Inhibitors; Estrenes; Ethanol; GABA Antagonists; GABA-B Receptor Agonists; In Vitro Techniques; Indoles; Male; Methoxyhydroxyphenylglycol; Mice; Mice, Inbred C57BL; Neural Inhibition; Neurons; Organophosphorus Compounds; Patch-Clamp Techniques; Pyrrolidinones; Receptors, Dopamine D2; Time Factors; Ventral Tegmental Area | 2011 |